Review of medical and surgical management of Clostridium difficile infection

Techniques in Coloproctology

Volumn 14, Issue 2, 2010, Pages 97-105

  Faris, B ^a   Blackmore, A ^b   Haboubi, N ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

Clostridium difficile; Croh s disease; Epidemiology; Inflammatory bowel diseases; Pseudomembranous enterocolitis; Risk factors; Treatment; Ulcerative colitis

Indexed keywords

BACITRACIN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE VACCINE; COLESTYRAMINE; FUSIDIC ACID; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; AGE; AUTOPSY; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; COLON RESECTION; COLONOSCOPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE CARRIER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY INTERVENTION; ENZYME IMMUNOASSAY; FECES ANALYSIS; HISTOPATHOLOGY; HUMAN; ILEUS; INFECTION CONTROL; LAPAROTOMY; MEDICAL DECISION MAKING; NONHUMAN; PROGNOSIS; PSEUDOMEMBRANOUS COLITIS; RECURRENCE RISK; RELAPSE; REVIEW; RISK ASSESSMENT; SEPSIS; SIGMOIDOSCOPY; SURGICAL TECHNIQUE; TOXIC MEGACOLON; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 77955701091     PISSN: 11236337     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10151-010-0574-3     Document Type: Review

References (130)

1. Aslam S, Hamill RJ, Musher DM (2005) Treatment of Clostridium difficile associated disease: old therapies and new strategies. Lancet Infect Dis 5:549-557
2. McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204-210
3. Hall IC, O'Toole E (1935) Intestinal flora in newborn infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 48:390-402
4. McFarland LV, Brandmarker SA, Guandalini S (2000) Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gastroenterol Nutr 31:220-231
5. Riggs MM, Sethi AK, Zabarsky TF et al (2007) Asymptomatic carriers are a potential source for transmission of epidemic and non-epidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45:992-998
6. Kyne L, Warny M, Qamar A, Kelly CP (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390-397
7. Sunenshine RH, McDonald LC (2006) Clostridium difficileassociated disease: new challenges from an established pathogen. Cleveland Clinic J Med 73:187-197
8. Hurley BW, Nguyen CC (2002) The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhoea. Arch Intern Med 162:2177-2184
9. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Healthcare costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile. Clin Infect Dis 34:346-353
10. Wilcox MH (2003) Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 17:475-493
11. Wilson KH (1993) The micro ecology of Clostridium difficile. Clin Infect Dis 16:214-218
12. Kelly CP, Pothoulakis C, LaMont JT (1994) Clostridium difficile colitis. N Engl J Med 330:257-262
13. Monaghan T, Boswell T, Mahida YR et al (2008) Recent advances in Clostridium difficile-associated disease. Gut 57:850-860
14. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40:1-15
15. Ricciardi R, Ogilvie JW, Roberts PL, Marcello PW, Concannon TW, Baxter NN (2009) Epidemiology of Clostridium difficile Colitis in hospitalised patients with inflammatory bowel disease. Dis Colon Rectum 52:40-45
16. Tonna I, Welsby PD (2005) Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J 81:367-369
17. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN (2008) A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 62:388-396
18. Aseeri M, Schroeder T, Kramer J et al (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile associated diarrhoea in hospitalised patients. Am J Gastroenterol 103:2308-2313
19. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S (2008) Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 179:767-772
20. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102:2047-2056
21. Lowe D, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006) Proton pump inhibitors and hospitalisation for Clostridium difficile associated disease: a population-based study. Clin Infect Dis 43:1272-1276
22. Hermsen JL, Dobrescu C, Kudsk KA (2008) Clostridium difficile: a surgical disease in evolution. J Gastrointest Surg 12:1512-1517
23. McFarland LV (2008) Update on the changing epidemiology of Clostridium difficile-associated disease. Nature Clin Pract 5:40-48
24. Burke GW, Wilson ME, Mehrez IQ (1988) Absence of diarrhoea in toxic megacolon complicating Clostridium difficile pseudomembranous colitis. Am J Gastroent 83:304-307
25. Viswanath YK, Griffith CD (1990) Role of surgery in antibiotic induced pseudomembranous colitis. Am J Surg 160:535-539
26. Bartlett JG (1990) Clostridium difficile: clinical considerations. Rev Infect Dis 12:S243-S251
27. Bartlett JG (2002) Clinical practice: antibiotic-associated diarrhea. N Eng J Med 346:334-339
28. Clostridium difficile infection (2008) How to deal with the problem, a board to ward approach. Department of Health Steering Group on Healthcare Associated Infection. Department of Health; Gateway Reference 9833
29. Diagnosis, Treatment, and Management of CDI (2008) An Expert Interview with Cassandra D. Salgado, MD, MS. Medscape Infectious Diseases. http://www.medscape.com/ viewarticle/576542
30. Pépin J, Valiquette L, Cossette B (2005) Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hyper virulent strain in Quebec. CMAJ 173:1037-1042
31. McDonald LC, Kilgore GE, Thompson A et al (2005) An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med 353:2433-2441
32. Matamouros S, England P, Dupuy B (2007) Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64:1274-1288
33. Cloud J, Kelly CP (2007) Update on Clostridium difficile associated disease. Cur Opin Gastroenterol 23:4-9
34. Kuijper EJ, van Dissel JT, Wilcox MH (2007) Clostridium difficile: changing epidemiology and new treatment options. Cur Opin Infect Dis 20:376-383
35. Hubert B, Loo VG, Bourgault AM et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile associated disease in Quebec. Clin Infect Dis 44:238-244
36. Warny M, Pepin J, Fang A et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084
37. Brazier JS, Raybould R, Patel B et al (2008) Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill 13:1-4
38. Goorhuis A, Bakker D, Corver J et al (2008) Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162-1170
39. Wilcox MH, Cunniffe JG, Trundle C, Redpath C (1996) Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 34:23-30
40. Somaiah A, Blencowe N, PYE G, West R (2009) Clostridium difficile: how much do hospital staff know about it. Ann R Coll Surg Engl 91:464-469
41. Deaths involving Clostridium difficile; England and Wales, 2003-2007 (2008) Health Stat Q:67-76
42. Jabbar A, Wright RA (2003) Gastroenteritis and antibioticassociated diarrhoea. Prim Care 30:63-80
43. Kyne L, Farrel RJ, Kelly CP (2001) Clostridium difficile. Gastroenterol Clin North Am 30:753-777
44. Guerrant RL, Van Gilder T, Steiner TS et al (2001) Practice guidelines for the management of infectious diarrhoea. Clin Infect Dis 32:331-351
45. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr (1995) Clostridium difficile-associated disease diarrhoea and colitis. Infect Control Hosp Epidemiol 16:459-477
46. Blossom DB, McDonald LC (2007) The challenges posed by re-emerging Clostridium difficile infection. Clin Infect Dis 45:222-227
47. NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing (CEP) (2008) Evaluation Report on Clostridium difficile toxin detection assays. CEP08054
48. Fenner L, Widmer AF, Goy G et al (2008) Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. Clin Microbiol 49:328-330
49. Finney JMT (1990) Gastro-enterostomy for cicatrising ulcer of the pylorus. Bull John Hopkins Hospital 4:53-55 (1893) (cited by Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 12:S243-S251)
50. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB (1978) Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298:531-534 (Pubitemid 8295586)
51. Chen FCS, Woods R (1994) Pseudomembranous pan-enteritis and septicaemia in a patient with ulcerative colitis. ANZ J of Surg 66:565-567
52. Morris LL, Villalba MR, Glover JL (1994) Management of pseudomembranous colitis. Am Surg 60:548-551
53. Goulston SJM, McGovern VJ (1965) Pseudomembranous colitis. Gut 6:207-212
54. Price AB, Davies DR (1977) Pseudomembranous colitis. J Clin Pathol 30:1-12
55. Yafi FA, Selvasekar CR, Cima RR (2008) Clostridium difficile enteritis following total colectomy. Tech Coloproctol 12:73-74
56. Borriello SP (1998) Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41:13-19
57. Tedesco FJ (1979) Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 77:295-297
58. Triadafilopoulos G, Hallstone AE (1991) Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 101:685-691
59. Spencer RC (1998) Clinical impact and associated costs of Clostridium difficile associated disease. J Antimicrob Chemother 41:5-12
60. Dallal RM, Harbrecht BG, Boujoukas AJ et al (2002) Fulminant Clostridium difficile: an under appreciated and increasing cause of death and complications. Ann Surg 235:363-372
61. Mallavarapu RK, Katner HP (2007) Clostridium difficile- associated diarrhoea and colitis in the hospitalised patient. Hosp Physician 21-27
62. Kyne L, Farrell RJ, Kelly CP (2001) Clostridium difficile. Gastroenterol Clin North 30:753-777
63. Poutanen SM, Simor AE (2004) Clostridium difficile-associated diarrhoea in adults. CMAJ 171:51-58
64. Tedesco FJ, Corless JK, Brownstein RE (1982) Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 83:1259-1260
65. Wanahita A, Goldsmith EA, Marino BJ, Musher DM (2003) Clostridium difficile infection in patients with unexplained leucocytosis. Am J Med 115:543-546
66. Wanahita A, Goldsmith EA, Musher DM (2002) Conditions associated with leucocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 34:1585-1592
67. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG (1995) Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123:835-840
68. Bartlett JG (1992) Antibiotic-associated diarrhoea. Clin Infect Dis 15:573-581
69. McFarland LV (2005) Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 54:101-111
70. Leung DY, Kelly CP, Boguniewicz M et al (1991) Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118:633-637
71. Aboudola S, Kotloff KL, Kyne L et al (2003) Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608-1610
72. Kelly CP (1996) Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 8:1048-1053
73. Fekety R, McFarland LV, Surawicz CM et al (1997) Recurrent Clostridium difficile diarrhoea: characteristics of and risk factors for patients enrolled in a prospective, randomised, double-blinded trial. Clin Infect Dis 24:324-333
74. McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769-1775
75. Johnson S, Schriever C, Galang M et al (2007) Interruption of recurrent Clostridium difficile-associated diarrhoea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44:846-848
76. Viswanath YK, Griffiths CD (1998) The role of surgery in pseudomembranous enterocolitis. Postgrad Med J 74:216-219
77. Miller MA (2007) Clinical management of Clostridium difficileassociated disease. Clin Infect Dis 45:S122-S128
78. Pépin J, Valiquette L, Alary ME et al (2004) Clostridium difficile- associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466-472
79. Novak E, Lee JG, Seckman CE et al (1976) Unfavorable effect of atropinediphenoxylate (Lomotil) therapy in lincomycincaused diarrhea. JAMA 235:1451-1454
80. Poutanen SM, Simor AE (2004) Clostridium difficile-associated diarrhea in adults. Can Med Assoc J 171:51-58
81. Bouza E, Munoz P, Alonso R (2005) Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 11:S57-S64
82. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302-307
83. Pépin J, Routhier S, Gagnon S, Brazeau I (2006) Management and outcomes of a first recurrence of Clostridium difficileassociated disease in Quebec, Canada. Clin Infect Dis 42:758-764
84. Louie T, Gerson M, Grimard D et al (2007) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile associated diarrhea. 47th Interscience conference on antimicrobial agents and chemotherapy, Chicago
85. Bouza E, Dryden M, Mohammed R et al (2008) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea. 18th European congress of clinical microbiology and infectious diseases
86. Pépin J, Valiquette L, Gagnon S et al (2007) Outcomes of Clostridium difficile associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/ 027. Am J Gastroenterol 102:2781-2788
87. Pépin J, Saheb N, Coulombe MA et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254-1260
88. Wilcox MH, Howe R (1995) Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 36:673-679
89. Musher DM, Aslam S, Logan N et al (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586-1590
90. Lahue BJ, Davidson DM (2007) Metronidazole and vancomycin outcomes for Clostridium difficile-associated diarrhoea in a US hospital database. European Conference on Clinical Microbiology and Infectious Diseases, Munich
91. Aas J, Ce Gessert, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via nasogastric tube. Clin Infect Dis 36:580-585
92. Giannasca PJ, Wary M (2004) Active and passive immunisation against Clostridium difficile diarrhoea and colitis. Vaccine 22:848-856
93. Kelly CP, LaMont JT (2008) Clostridium difficile-more difficult than ever. N Engl J Med 359:1932-1940
94. Tedesco FJ, Gordon D, Fortson WC (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80:867-868
95. Nelson R (2007) Antibiotic treatment for Clostridium difficileassociated diarrhoea in adults. Cochrane Database Syst Rev CD004610
96. Salcedo J, Keates S, Pothoulakis C et al (1997) Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41:366-370
97. Warny M, Denie C, Delmee M, Lefebvre C (1995) Gamma globulin administration in relapsing Clostridium difficileinduced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 50:36-39
98. Juang P, Skledar SJ, Zgheib NK et al (2007) Clinical outcomes of intravenous immunoglobulin in severe Clostridium difficileassociated diarrhoea. Am J Infect Control 35:131-137
99. Pillai A, Nelson R (2008) Probiotics for treatment of Clostridium difficile associated colitis in adults. Cochrane Database Syst Rev 1:CD004611
100. Taylor NS, Bartlett JG (1980) Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141:92-97
101. Tedesco FJ (1982) Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 77:220-221
102. Hookman P, Barkin JS (2009) Clostridium difficile associated infection, diarrhoea and colitis. World J Gastroenterol 15:1554-1580
103. Louie TJ, Peppe J, Watt CK et al (2006) Tolevamer, a novel non-antibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficileassociated diarrhoea. Clin Infect Dis 43:411-431
104. Borody T, Warren E, Leis S, Surace R, Ashman O, Siarakas S (2004) Bacteriotherapy using faecal flora: toying with human motions. J Clin Gastroenterol 38:475-483
105. Borody T, Warren E, Leis S, Surace R, Ashman O (2003) Treatment of ulcerative colitis using faecal bacteriotherapy. J Clin Gastroenterol 37:42-47
106. McMaster-Baxter NL, Musher DM (2007) Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 27:1029-1039
107. Starr J (2005) Clostridium difficile-associated diarrhoea: diagnosis and treatment. BMJ 331:498-501
108. Gourevitch D, Hawkey P (2009) Clostridium difficile infection and surgery. Br J Surg 96:3-4
109. Noblett SE, Welfare M, Seymour K (2009) The role of surgery in Clostridium difficile colitis. BMJ 338:1196-1200
110. Koss K, Clark MA, Sanders DSA, Morton D, Keighley MRB, Goh J (2005) The outcome of surgery in fulminant Clostridium difficile colitis. Col Dis 8:149-154
111. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R (1998) Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 85:229-231
112. Pepin J, Truc Vo T, Boutros M et al (2009) Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 52:400-405
113. Hall JF, Berger D (2008) Outcome of colectomy for colitis: a plea for early surgical management. Am J Surg 196:384-388 (Clostridium difficile)
114. Ali SO, Welch JP, Dring RJ (2008) Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 74:20-26
115. Nelson RL, Glenny AM, Song F (2009) Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev 1. doi: 10.1002/14651858. CD001181.pub3 (Art. No.: CD001181)
116. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhoea. N Engl J Med 346:1079-1084
117. Bulstrode NW, Bradbury AW, Barrett S et al (1997) Clostridium difficile colitis after aortic surgery. Eur J Vasc Endovasc Surg 14:217-220 (Pubitemid 27448109)
118. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE (2004) Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 47:1620-1626
119. Ash L, Baker ME, O'Malley CM Jr, Gordon SM, Delaney CP, Obuchowski NA (2006) Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. Am J Roent 186:1393-1400
120. Byrn JC, Maun DC, Gingol DS, Baril DT, Ozao JJ, Divino CM (2008) Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 143:150-154
121. Jaber MR, Olafsson S, Fung WL, Reeves ME (2008) Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastro 103:3195-3203
122. Gash K, Brown E, Pullyblank A (2010) Emergency subtotal colectomy for fulminant Clostridium difficile Colitis is a surgical solution considered for all patients? Ann R Coll Surg Engl 92:56-60
123. Lipsett PA, Samantary DK, Tam ML, Bartlett JG, Lillemoe KD (1994) Pseudomembranous colitis: a surgical disease? Surgery 116:491-496
124. Seder CW, Villalba MR Jr, Robbins J et al (2009) Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 197:302-330
125. Issa M, Ananthakrishnan N, Binion DG (2008) Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 14:1432-1442
126. Freeman HJ (2008) Recent development on the role of Clostridium difficile in inflammatory bowel disease. World J Gastroenterol 14:2794-2796
127. Monaghna T, Boswell T, Mahida R (2009) Recent advances in Clostridium difficile associated diseases. Postgrad Med J 85:152-162
128. Ananthakrishnan AN, McGinley EL, Binion DG (2008) Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57:210-256
129. Stone CD (2008) Prognosis in Clostridium difficile infection complication inflammatory bowel disease. Gut 57:150-152
130. Jodorkovsky D, Young Y, Abreu MT (2010) Clinical outcomes of patients with ulcerativecolitis and co-existing Clostridium difficile infection. Dig Dis Sci 55:415-420